• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.50% Nasdaq Down0.61%

    Keryx Biopharmaceuticals Inc. (KERX)

    5.57 Up 0.31(5.89%) 1:22PM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    Keryx Biopharmaceuticals Inc.
    One Marina Park Drive
    12th Floor
    Boston, MA 02210
    United States - Map
    Phone: 617-466-3500
    Fax: 617-466-3501
    Website: http://www.keryx.com

    Index Membership:N/A
    Full Time Employees:184

    Business Summary 

    Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Keryx Biopharmaceuticals Inc.

    Corporate Governance 
    Keryx Biopharmaceuticals Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 5; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Gregory P. Madison , 48
    Chief Exec. Officer, Pres, Director and Member of R&D Committee
    Mr. Scott A. Holmes M.S., M.B.A., CPA, 42
    Chief Financial Officer and Treasurer
    Mr. Brian R. Adams , 42
    Gen. Counsel and Sec.
    Dr. John F. Neylan M.D., 63
    Chief Medical Officer
    Lora Pike ,
    Sr. Director of Investor Relations
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders